NCT07525219 Suzetrigine Frame Trial Comparing Suzetrigine and Acetaminophen
| NCT ID | NCT07525219 |
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | Wake Forest University Health Sciences |
| Condition | Analgesic Efficacy |
| Study Type | INTERVENTIONAL |
| Enrollment | 80 participants |
| Start Date | 2026-06-22 |
| Primary Completion | 2027-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 3 trials are large pivotal studies comparing the treatment to current standard of care or placebo. Your participation directly contributes to the evidence needed for regulatory approval.
This trial targets 80 participants in total. It began in 2026-06-22 with a primary completion date of 2027-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Local anesthetic infiltration is a primary source of acute pain during stereotactic procedures.
Eligibility Criteria
Inclusion Criteria: * Patients scheduled for a standard of care procedure requiring a stereotactic head frame to be placed Exclusion Criteria: * Patients not scheduled for a standard of care procedure requiring a stereotactic head frame to be placed will not be approached
Contact & Investigator
Stephen B Tatter, MD
PRINCIPAL INVESTIGATOR
Wake Forest University Health Sciences
Frequently Asked Questions
Who can join the NCT07525219 clinical trial?
This trial is open to participants of all sexes, aged 21 Years or older, studying Analgesic Efficacy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07525219 trial and what does that mean for participants?
Phase 3 trials are large-scale studies comparing the new treatment to existing standards of care or a placebo. They provide the evidence needed for regulatory approval. This trial targets 80 participants.
Is NCT07525219 currently recruiting?
Yes, NCT07525219 is actively recruiting participants. Contact the research team at Wendy.Jenkins@AdvocateHealth.org for enrollment information.
Where is the NCT07525219 trial being conducted?
This trial is being conducted at Winston-Salem, United States.
Who is sponsoring the NCT07525219 clinical trial?
NCT07525219 is sponsored by Wake Forest University Health Sciences. The principal investigator is Stephen B Tatter, MD at Wake Forest University Health Sciences. The trial plans to enroll 80 participants.